The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial

Launched by CENTRO DE ATENÇÃO AO ASSOALHO PÉLVICO · May 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying different methods to treat overactive bladder in women, a condition that causes frequent and urgent need to urinate, which can greatly affect daily life. The trial compares three treatment options: a technique called parasacral transcutaneous electrical stimulation, tibial transcutaneous electrical stimulation, and a home-based treatment protocol. Women aged 18 to 65 who experience symptoms of overactive bladder may be eligible to participate, but those with certain medical conditions or difficulties understanding the study will not be included.

Participants in the trial will receive guidance on behavioral therapy and will be given an educational booklet. They will undergo treatments three times a week for about 10 weeks, using a device that sends gentle electrical signals to help improve bladder control. Throughout the study, participants will answer questions about their symptoms, quality of life, and mental health, and they'll be followed for at least a year to assess the long-term effects of the treatments. The hope is that the parasacral stimulation will be more effective in reducing symptoms compared to the tibial stimulation.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with symptoms of overactive bladder, aged 18 to 65 years.
• Exclusion Criteria:
• • Participants who have difficulty understanding the stages of the research, report cognitive deficit or psychiatric illness, patients with congenital orthopedic / neurological diseases, overactive bladder due to neurological impairment, presence of lower urinary tract infection, sensory deficit in the sacral or tibial region, diagnosis of chronic renal failure, patients with pacemakers and implantable cardioverter defibrillators and pregnant women.